Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY from December 3-5, 2024.
宾夕法尼亚州新希望,2024年11月26日(环球新闻网络)-- Orchestra BioMed Holdings, Inc.(纳斯达克:OBIO,"Orchestra BioMed"或"公司"),一家通过风险回报共享合作伙伴关系加速高影响力技术向患者提供的生物医药公司,今天宣布公司管理层将在2024年12月3日至5日在纽约举行的派杰投资第36届年度医疗会议上进行演讲,并可进行一对一会议。
Details of the presentation are shown below.
以下是演示的详细信息。
Format: Fireside Chat
Date: Wednesday, December 4, 2024
Time: 3:00 PM EST
Webcast:
格式:炉边聊天
日期:2024年12月4日星期三
时间:下午3:00 东部标准时间
网络直播:
A replay of the webcast will be available on the Events section of the Orchestra BioMed website for 90 days following the presentation.
演示的网络广播回放将在乐队生物医疗网站的活动部分提供,持续90天。
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit , and follow us on LinkedIn.
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIm therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAb for the treatment of artery disease. For further information about Orchestra BioMed, please visit , and follow us on LinkedIn.
References to Websites and Social Media Platforms
有关网站和社交媒体平台的引用信息的参考资料不构成包含在此类网站或社交媒体平台上的信息的引用,并且您不应将此类信息视为本新闻稿的一部分。
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.
关于高血压及起搏器患者高血压风险
Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
484-682-4892
Kkirkellis@orchestrabiomed.com
联系方式:
凯尔西·柯克-埃利斯
乐团生物医学
484-682-4892
Kkirkellis@orchestrabiomed.com